4.8 Review

Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases

期刊

GASTROENTEROLOGY
卷 156, 期 8, 页码 2174-2189

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2019.03.017

关键词

Microbiome; Inflammatory Bowel Disease; Host Genetics; Mucosal Immunity; Preclinical Therapies

资金

  1. National Institutes of Health [K08 DK109287-01, U01 DK62429, U01 DK062422, R01 DK092235, R01 DK106593, R00 DK110534]
  2. Sanford J. Grossman Center for Integrative Studies in Crohn's Disease

向作者/读者索取更多资源

The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans and colitis in mice. We review genetic variants associated with IBD and their effects on the intestinal microbiome, the immune response, and disease pathogenesis. The intestinal microbiome, which includes microbial antigens, adjuvants, and metabolic products, affects the development and function of the intestinal mucosa, influencing inflammatory responses in the gut. Therefore, strategies to manipulate the microbiome might be used in treatment of IBD. We review microbe-based therapies for IBD and the potential to engineer patients' intestinal microbiota. We discuss how studies of patients with IBD and mouse models have advanced our understanding of the interactions between genetic factors and the gut microbiome, and challenges to the development of microbe-based therapies for IBD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据